new Alzheimer’s treatment is a Trojan horse that presages more sweeping limits on medical spending. But the decision is unlikely to be a precedent given how much is exceptional in this story.
The U.S. Food and Drug Administration’s approval of the drug in June went against an advisory panel that concluded there was insufficient evidence of its efficacy. A U.S. government watchdog said in August it would review the approval process. Meanwhile insurers have been reluctant to pay, and doctors to prescribe it, so Biogen cut the price of the drug by about halfTrue, the potential cost is worrisome. An effective Alzheimer’s drug might reap $20 billionannually.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Source: FoxBusiness - 🏆 458. / 53 Read more »
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Source: Reuters - 🏆 2. / 97 Read more »
Medicare plans to pay for controversial Alzheimer’s drug, if patients enroll in trialsMedicare plans to provide insurance coverage for Aduhelm, a controversial Alzheimer’s treatment from drugmaker Biogen.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial PatientsThe Centers for Medicare and Medicaid Services said it will cover the cost of the drug Aduhelm, but as part of further clinical testing.
Source: WSJhealth - 🏆 413. / 53 Read more »
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Source: Reuters - 🏆 2. / 97 Read more »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Source: FoxBusiness - 🏆 458. / 53 Read more »